Clopidogrel resistance is a common condition, and its incidence can vary depending on ancestry. About half of individuals with Asian ancestry have clopidogrel resistance, with 10 percent of these individuals classified as poor metabolizers. Objective: To report upon the safety/effectiveness of ticagrelor in patients with cerebrovascular diseases and clopidogrel resistance undergoing angioplasty and/or stent or flow diverter placement. Results of PRU before and after the addition of cilostazol to clopidogrel resistance revealed that PRU after the addition of cilostazol was significantly lower than PRU before the addition of cilostazol in the IM and PM groups (IM group: 205.6 ± 74.0 vs 254.3 ± 35.0, P = 0.02 and Purpose: The purpose of the study was to assess clopidogrel resistance and whether “intensified” antiplatelet therapy guided by platelet inhibition tests during neuroendovascular procedures would reduce ischemic complications. 아스피린과 P2Y 12 수용체 억제제인 클로피도그렐(clopidogrel) 복합요법은 최근까지 관상동맥 중재술(percutaneous coronary intervention, PCI)을 시행하거나 급성 관상동맥 증후군(acute coronary syndrome, ACS)을 앓은 고위험군의 CAD 치료에 널리 이용되어 왔다. Clopidogrel resistance rate using 2 cut-off PRU values (235 and 208) did not change significantly in DM and non DM patients. Conclusions RF significantly decreased platelet sensitivity to clopidogrel in DM patients during and after Ramadan. Measuring aspirin resistance, clopidogrel responsiveness, and postprocedural markers of myonecrosis in patients undergoing percutaneous coronary intervention. Buch AN(1), Singh S, Roy P, Javaid A, Smith KA, George CE, Pichard AD, Satler LF, Kent KM, Suddath WO, Waksman R. Campo G, Fileti L, de Cesare N, et al. Long-term clinical outcome based on aspirin and clopidogrel responsiveness status after elective percutaneous coronary intervention: a 3T/2R (tailoring treatment with tirofiban in patients showing resistance to aspirin and/or resistance to clopidogrel) trial substudy. J Am Coll Cardiol 2010; 56:1447. clopidogrel using RPFA in patients with ischemic stroke, and to identify the clinical factor related with clopidogrel resistance. Methods: A total of 86 patients taking clopidogrel (75 mg/day) were enrolled. These studies contend that the phenomenon of clopidogrel resistance may appear in 4–30% of studied subjects , , . However, these numbers are somewhat speculative, and there is a need to assess the optimal degree of clopidogrel-induced platelet inhibition and how it correlates with clopidogrels ability to prevent atherothrombotic events [10].